A Study of Tebapivat (AG-946) in Participants With Anemia Due to Lower-Risk Myelodysplastic Syndromes (LR-MDS)
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.
Myelodysplastic Syndromes
DRUG: Tebapivat
Phase 2a: Proportion of Participants With Hemoglobin (Hb) Response, Hb response is defined as a ≥1.5-grams per deciliter (g/dL) increase from baseline in the average Hb concentration from Week 8 through Week 16., Baseline, Week 8 through Week 16|Phase 2a: Proportion of Participants With Transfusion Independence During the Core Period, Transfusion Independence is defined as transfusion-free for ≥8 consecutive weeks during the Core Period (participants With Low Transfusion Burden \[LTB\] only)., Up to 16 weeks|Phase 2b: Proportion of Participants With Transfusion Independence, Transfusion independence, defined as transfusion-free for ≥8 consecutive weeks (TI8) during the Core Period., Up to 24 weeks
Phase 2a: Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation During the Core Period, An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An SAE is any AE or suspected adverse reaction that results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly/birth defect, or is considered an important medical event., Up to 16 weeks|Phase 2a: Proportion of Participants With Laboratory Abnormalities During the Core Period, Up to 16 weeks|Phase 2a: Proportion of Participants With Hb 1.0+ Response, Hb 1.0+ response is defined as a ≥1.0-g/dL increase from baseline in the average Hb concentration from Week 8 through Week 16, Baseline, Week 8 through Week 16|Phase 2a: Change From Baseline in Hb Concentration During the Core Period, Baseline up to 16 weeks|Phase 2a: Proportion of Participants With ≥1.5-g/dL increase From Baseline in the Hb Concentration at ≥2 Consecutive Time Points From Week 8 through Week 16, Baseline, Week 8 through Week 16|Phase 2a: Change from Baseline in Total Transfused Red Blood Cell (RBC) Units During the Core Period, Baseline up to 16 weeks|Phase 2a: Proportion of Participants With ≥50% Reduction in Total Transfused RBC Units for ≥8 Consecutive Weeks During the Core Period Compared With Baseline, Baseline up to 16 weeks|Phase 2a: Plasma Concentration of Tebapivat During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2a: Maximum (Peak) Concentration (Cmax) of Tebapivat During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2a: Time to Cmax (tmax) of Tebapivat During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2a: Area Under the Concentration-time Curve From 0 to t Hours (AUC0-t) of Tebapivat During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2a: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval (AUC0-τ) of Tebapivat During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2a: Apparent Terminal Elimination Half-life (t½) of Tebapivat During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2a: Whole Blood Concentrations of 2,3-diphosphoglycerate (2,3-DPG) During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2a: Whole Blood Concentrations of Adenosine Triphosphate (ATP) During the Core Period, Day 1 and Week 8 (≤60 minutes predose and 0.5, 1, 2, 3, 4, 6, and 8 hours postdose) and at Weeks 2, 4, 12, and 16 (≤60 minutes predose)|Phase 2b: Proportion of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), and AEs Leading to Discontinuation During the Core Period, An AE is any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product that does not necessarily have a causal relationship with this treatment. An SAE is any AE or suspected adverse reaction that results in death, is immediately life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, results in congenital anomaly/birth defect, or is considered an important medical event., Up to 24 weeks|Phase 2b: Proportion of Participants With Laboratory Abnormalities During the Core Period, Up to 24 weeks|Phase 2b: Change From Baseline in Hb Concentration During the Core Period, Baseline up to 24 weeks|Phase 2b: Change From Baseline in Total Transfused RBC Units From Week 8 Through Week 24, Baseline, Week 8 through Week 24|Phase 2b: Proportion of Participants With ≥50% Reduction in Total Transfused RBC Units for ≥8 Consecutive Weeks During the Core Period Compared With Baseline, Baseline up to 24 weeks|Phase 2b: Time to First TI8 During the Core Period, Baseline up to 24 weeks|Phase 2b: Proportion of Participants Who Become Transfusion-free for ≥12 Consecutive Weeks (TI12) During the Core Period, Up to 24 weeks|Phase 2b: Proportion of Participants With ≥50% Reduction in Total Transfused RBC Units for ≥12 Consecutive Weeks During the Core Period Compared With Baseline, Baseline up to 24 weeks|Phase 2b: Time to First TI12 During the Core Period, Baseline up to 24 weeks|Phase 2b: Duration of Transfusion Independence (TI), The duration of TI will be calculated as the number of days in the longest transfusion-free period starting on or after the start of study treatment through the end of the Core Period., Baseline up to 24 weeks|Phase 2b: Plasma Concentration of Tebapivat During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20|Phase 2b: Maximum (Peak) Concentration (Cmax) of Tebapivat During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20|Phase 2b: Time to Cmax (tmax) of Tebapivat During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20|Phase 2b: Area Under the Concentration-time Curve From 0 to t Hours (AUC0-t) of Tebapivat During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20|Phase 2b: Area Under the Concentration-time Curve From 0 to the End of the Dosing Interval (AUC0-τ) of Tebapivat During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20|Phase 2b: Apparent Terminal Elimination Half-life (t½) of Tebapivat During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20|Phase 2b: Whole Blood Concentrations of 2,3-diphosphoglycerate (2,3-DPG) During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20|Phase 2b: Whole Blood Concentrations of Adenosine Triphosphate (ATP) During the Core Period, Predose and multiple time points post dose from Day 1 up to Week 20
This purpose of this study is to establish proof of concept of tebapivat in participants with LR-MDS in Phase 2a and to evaluate the effect of tebapivat on transfusion independence (TI) in participants with LR-MDS in phase 2b.